

ACR Appropriateness Criteria[®] Radiologic Management of Iliofemoral Venous Thrombosis

Expert Panel on Interventional Radiology: *Khashayar Farsad, MD, PhD^a, Baljendra S. Kapoor, MD^b, Nicholas Fidelman, MD^c, Thomas R. Cain, MD^d, Drew M. Caplin, MD^e, Jens Eldrup-Jorgensen, MD^f, Amit Gupta, MD^g, Mikhail Higgins, MD, MPH^h, Eric J. Hohenwalter, MDⁱ, Margaret H. Lee, MD^j, Joseph J. McBride, MD^k, Jeet Minocha, MD^l, Paul J. Rochon, MD^m, Patrick D. Sutphin, MD, PhDⁿ, Jonathan M. Lorenz, MD^o*

Abstract

Iliofemoral venous thrombosis carries a high risk for pulmonary embolism, recurrent deep vein thrombosis, and post-thrombotic syndrome complicating 30% to 71% of those affected. The clinical scenarios in which iliofemoral venous thrombosis is managed may be diverse, presenting a challenge to identify optimum therapy tailored to each situation. Goals for management include preventing morbidity from venous occlusive disease, and morbidity and mortality from pulmonary embolism. Anticoagulation remains the standard of care for iliofemoral venous thrombosis, although a role for more aggressive therapies with catheter-based interventions or surgery exists in select circumstances. Results from recent prospective trials have improved patient selection guidelines for more aggressive therapies, and have also demonstrated a lack of efficacy for certain conservative therapies.

The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.

^aCharles T. Dotter Department of Interventional Radiology, Portland, Oregon.

^bPanel Chair, Cleveland Clinic, Cleveland, Ohio.

^cPanel Vice-Chair, University of California San Francisco, San Francisco, California.

^dDesert Regional Medical Center, Palm Springs, California.

^eZucker School of Medicine at Hofstra Northwell, Hempstead, New York.

^fTufts University School of Medicine, Boston, Massachusetts; Society for Vascular Surgery.

^gRenaissance School of Medicine at Stony Brook University, Stony Brook, New York.

^hBoston University School of Medicine, Boston, Massachusetts.

ⁱFroedtert & The Medical College of Wisconsin, Milwaukee, Wisconsin.

^jDavid Geffen School of Medicine at UCLA, Los Angeles, California.

^kUniversity of Nebraska Medical Center, Omaha, Nebraska.

^lUniversity of California San Diego, San Diego, California.

^mUniversity of Colorado Denver Anschutz Medical Campus, Aurora, Colorado.

ⁿUT Southwestern Medical Center, Dallas, Texas.

^oSpecialty Chair, University of Chicago Hospital, Chicago, Illinois.

Corresponding author: Khashayar Farsad, MD, PhD, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97221; e-mail: farsad@ohsu.edu.

The American College of Radiology seeks and encourages collaboration with other organizations on the development of the ACR Appropriateness Criteria through society representation on expert panels. Participation by representatives from collaborating societies on the expert panel does not necessarily imply individual or society endorsement of the final document.

Reprint requests to: publications@acr.org.

Dr Farsad reports other from Auxetics, Inc, personal fees from Cook Medical, personal fees from BTG, personal fees from Neuwave, grants and personal fees from Guerbet, LLC, personal fees from Genentech, personal fees from Dova Pharmaceuticals, outside the submitted work; In addition, Dr Farsad has a patent "use of specific stent class for the management of venous stenosis" licensed to Auxetics, Inc. Dr Rochon reports support from Penumbra, support from Medtronic outside the submitted work. The other authors state that they have no conflict of interest related to the material discussed in this article.

Disclaimer: The ACR Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of specified medical condition(s). These criteria are intended to guide radiologists, radiation oncologists and referring physicians in making decisions regarding radiologic imaging and treatment. Generally, the complexity and severity of a patient's clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those examinations generally used for evaluation of the patient's condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of appropriate imaging procedures or treatments. Imaging techniques classified as investigational by the FDA have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any specific radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination.

Key Words: Appropriateness Criteria, Appropriate Use Criteria, AUC, Catheter-directed therapy, Deep vein thrombosis (DVT), Iliofemoral venous thrombosis, Thrombolysis, Venous stent

J Am Coll Radiol 2020;17:S255-S264. Copyright © 2020 American College of Radiology

ACR Appropriateness Criteria® Radiologic Management of Iliofemoral Venous Thrombosis. [Variants 1 to 7](#) and [Table 1](#).

Variant 1. Acute iliofemoral DVT with mild symptoms less than 14 days, otherwise healthy.

Procedure	Appropriateness Category
Anticoagulation alone	Usually Appropriate
CDT/PMT with or without stent placement	Usually Not Appropriate
Graded compression stocking therapy	May Be Appropriate
Surgical thrombectomy techniques	Usually Not Appropriate

Variant 2. Acute iliofemoral DVT with moderate to severe symptoms present for less than 14 days, otherwise healthy.

Procedure	Appropriateness Category
Anticoagulation alone	Usually Appropriate
CDT/PMT with or without stent placement	Usually Appropriate
Surgical thrombectomy techniques	May Be Appropriate

Variant 3. Acute femoropopliteal DVT with mild to moderate symptoms present for less than 14 days, otherwise healthy.

Procedure	Appropriateness Category
Anticoagulation alone	Usually Appropriate
CDT/PMT	Usually Not Appropriate
Graded compression stocking therapy	May Be Appropriate

Variant 4. Acute iliofemoral DVT and symptoms less than 14 days. Cross-sectional imaging consistent with May-Thurner syndrome.

Procedure	Appropriateness Category
Anticoagulation alone	May Be Appropriate
CDT/PMT with or without stent placement	Usually Appropriate
Hybrid surgical thrombectomy with stenting	May Be Appropriate

Variant 5. Acute iliofemoral DVT and limb-threatening ischemia (phlegmasia cerulea dolens).

Procedure	Appropriateness Category
Anticoagulation alone	Usually Not Appropriate
CDT/PMT with or without stent placement	Usually Appropriate
Surgical thrombectomy with or without stent placement	Usually Appropriate
Systemic thrombolysis	May Be Appropriate

Variant 6. Iliofemoral DVT with persistent moderate symptoms at least 3 months after initial treatment with anticoagulation alone.

Procedure	Appropriateness Category
Anticoagulation alone	May Be Appropriate
CDT/PMT with or without stent placement	May Be Appropriate
Graded compression stocking therapy	May Be Appropriate
Surgical thrombectomy with or without stent placement	May Be Appropriate (Disagreement)

Variant 7. Acute iliofemoral DVT in a pregnant patient with moderate to severe symptoms.

Procedure	Appropriateness Category
Anticoagulation alone	Usually Appropriate
CDT/PMT with or without stent placement	May Be Appropriate
Graded compression stocking therapy	May Be Appropriate
Surgical thrombectomy with or without stent placement	May Be Appropriate

Table 1. Appropriateness category names and definitions

Appropriateness Category Name	Appropriateness Rating	Appropriateness Category Definition
Usually Appropriate	7, 8, or 9	The imaging procedure or treatment is indicated in the specified clinical scenarios at a favorable risk-benefit ratio for patients.
May Be Appropriate	4, 5, or 6	The imaging procedure or treatment may be indicated in the specified clinical scenarios as an alternative to imaging procedures or treatments with a more favorable risk-benefit ratio, or the risk-benefit ratio for patients is equivocal.
May Be Appropriate (Disagreement)	5	The individual ratings are too dispersed from the panel median. The different label provides transparency regarding the panel's recommendation. "May be appropriate" is the rating category and a rating of 5 is assigned.
Usually Not Appropriate	1, 2, or 3	The imaging procedure or treatment is unlikely to be indicated in the specified clinical scenarios, or the risk-benefit ratio for patients is likely to be unfavorable.

SUMMARY OF LITERATURE REVIEW

Introduction/Background

Venous thromboembolic disease (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), carries significant morbidity and economic burden with an estimated annual \$7 to 10 billion in health expenditures and 375,000 to 425,000 incidence of new cases per year in the United States alone [1]. In addition to the risks of fatal PE, VTE is associated with high rates of recurrent DVT, post-thrombotic syndrome (PTS), and chronic PE with significant impacts on patient quality of life [1]. Management of VTE is multidisciplinary with potential involvement of providers from specialties and subspecialties including internal medicine, family practice, hematology/oncology, pulmonology, cardiology, vascular

surgery, and interventional radiology. Iliofemoral venous thrombosis carries high risk for PE, recurrent DVT, and PTS [2] with reported estimates of PTS ranging from 30% to 71% of those with iliofemoral DVT [2,3]. Goals for management include preventing morbidity from venous occlusive disease as well as preventing morbidity and mortality from PE.

Overview of Diagnostic and Therapeutic Options

In general, the standard of care for iliofemoral VTE is anticoagulation in patients without a contraindication [4]. Depending on the circumstance, cross-sectional imaging may be appropriate to assess for an underlying obstructive

cause, such as a venous compression syndrome or mass. In addition, ultrasound or CT may be helpful to differentiate chronic from acute DVT [2]. Patients with an underlying anatomic compression syndrome (eg, May-Thurner syndrome) amenable to intervention or surgery generally have this addressed in addition to receiving anticoagulation therapy. There may be differences in the anticoagulation regimens prescribed for patients, depending on the clinical scenario (eg, cancer-related VTE, pregnancy-related VTE, or VTE in the setting of renal impairment). Although in some instances, there may be a role for more aggressive therapy with catheter-based interventions or surgery in addition to anticoagulation, anticoagulation alone remains the pillar of care.

DISCUSSION OF PROCEDURES BY VARIANT

Variant 1: Acute iliofemoral DVT with mild symptoms less than 14 days, otherwise healthy

Anticoagulation Alone. The first-line therapy for acute iliofemoral DVT with mild symptoms is anticoagulation [5]. Therapy is indicated, even in the absence of symptoms, to prevent recurrent VTE. Duration of anticoagulation is generally at least 3 months, with indefinite anticoagulation indicated for those with unprovoked DVT and otherwise without contraindication, such as a significant bleeding risk with anticoagulation [5]. Those with a contraindication to anticoagulation may be considered for inferior vena cava filter placement [6,7].

CDT/PMT With or Without Stent Placement. Two large prospective randomized controlled trials, The Norwegian-based Catheter-directed Venous Thrombolysis (CaVenT) trial and the United States–based Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis (ATTRACT) trial, attempted to address whether improved early venous patency results in reduced PTS with rigorous trial designs comparing catheter-based therapies with thrombolysis and anticoagulation to standard-of-care anticoagulation alone. Five-year outcomes from the CaVenT trial demonstrated improved venous disease grading scores with reduction in PTS in those treated with catheter-directed thrombolysis (CDT) compared with anticoagulation alone (43% versus 71%, $P <.0001$) [3]. Despite this, the two arms did not differ in patient quality-of-life measures. The larger ATTRACT trial showed no overall difference in PTS outcomes between patients randomized to CDT versus anticoagulation alone (47% versus 48%, $P = .56$) despite significant decreases in PTS severity scores as measured by the Villalta scale and Venous Clinical Severity Score (VCSS)

[8]. The incidence of major bleeding was greater in those treated with CDT (1.7% versus 0.03%, $P = .049$). Thus, based on these recent prospective randomized trials, there is currently no role for catheter-based therapies in this cohort with mild symptoms to reduce PTS [3,8].

Graded Compression Stocking Therapy. Graded compression therapy with stockings has traditionally been recommended to address venous stasis changes and potentially prevent PTS; however, several recent randomized trials have found no specific benefit to compression therapy in preventing PTS [9–14]. Use of graded compression stockings in conjunction with additional measures, such as frequent leg elevation, may be recommended in addition to anticoagulation on an individualized basis for patient comfort and symptom management.

Surgical Thrombectomy Techniques. The Society of Vascular Surgery guidelines generally recommend catheter-based therapies over open surgery for VTE and, as such, surgical thrombectomy would not be recommended for mildly symptomatic or asymptomatic iliofemoral DVT considering the risk-to-benefit ratio [15].

Variant 2: Acute iliofemoral DVT with moderate to severe symptoms present for less than 14 days, otherwise healthy

Acute proximal DVT, defined as involvement of the iliac and upper femoral venous system, carries a high risk of PE [2,5]. Morbidity associated with proximal iliofemoral DVT includes recurrent DVT or PE and PTS, which consists of lower-extremity pain, swelling, venous claudication, and venous stasis, potentially leading to venous ulceration. For these reasons, treatment for acute proximal iliofemoral DVT is indicated [5].

Anticoagulation Alone. Anticoagulation with heparin, vitamin K antagonist, or direct oral anticoagulants are recommended as a first-line therapy, with newer guidelines suggesting preference for the direct oral anticoagulants in patients without cancer because of a reduced bleeding risk and better patient convenience [5]. Duration of anticoagulation generally lasts for at least 3 months, with indications for indefinite anticoagulation remaining for those with unprovoked DVT and otherwise without contraindication to or significant bleeding risk with anticoagulation [5].

CDT/PMT With or Without Stent Placement. There has been considerable interest in more aggressive measures to quickly remove thrombus burden in acute iliofemoral DVT to minimize valvular damage that can lead to PTS, termed the “open vein” hypothesis. Studies have consistently demonstrated improved early venous patency rates in

patients undergoing CDT or pharmacomechanical thrombectomy (PMT) with angioplasty or stenting of obstructive lesions relative to anticoagulation alone [16]. Two large prospective randomized controlled trials, the CaVenT trial and the ATTRACT trial, attempted to address whether improved early venous patency resulted in reduced PTS with rigorous trial designs comparing catheter-based therapies with thrombolysis and anticoagulation to standard-of-care anticoagulation alone. Five-year outcomes from the CaVenT trial demonstrated improved venous disease grading scores with reduction in PTS in those treated with CDT compared with anticoagulation alone (43% versus 71%, $P < .0001$) [3]. Despite this, the two arms did not differ in patient quality-of-life measures. The larger ATTRACT trial showed no overall difference in PTS outcomes between patients randomized to CDT versus anticoagulation alone (47% versus 48%, $P = .56$) despite significant decreases in PTS severity scores as measured by the Villalta scale and VCSS [8]. The incidence of major bleeding was greater in those treated with CDT (1.7% versus 0.03%, $P = .049$), with no reported fatal intracranial hemorrhage. A subgroup analysis of 391 prospectively stratified patients within the ATTRACT trial who had acute DVT involving iliac and/or common femoral veins (ie, the subgroup with more proximal DVT involving larger central veins) found a benefit to additional CDT in this cohort relative to anticoagulation alone, particularly in those < 65 years of age [17]. The benefits included significant improved early reduction in leg pain and swelling ($P < .01$), reduced PTS severity through 24 months ($P < .01$), and a decreased proportion of patients with moderate or severe PTS (Villalta scale > 10 or ulcer: 18% versus 28%; relative risk [RR] 0.65, $P = .021$; Villalta scale > 15 or ulcer: 8.7% versus 15%; RR 0.57, $P = .048$; VCSS > 8 : 6.6% versus 14%; RR 0.46, $P = .013$) despite no differences in the overall incidence of PTS at 2 years. Furthermore, significant improvement in venous-specific quality-of-life scores were noted in the cohort receiving CDT compared with anticoagulation alone ($P = .029$), despite no difference in generic quality of life ($P > .20$). Moreover, in this subgroup, additional CDT did not result in increased major bleeding relative to anticoagulation alone (1.5% versus 0.5%, $P = .32$). Part of the challenge in interpreting the apparent discrepancy between lack of measurable change in generic quality-of-life assessments, despite decreases in severity or incidence of PTS according to venous grading scales in these two studies, may rest in the relatively broad range of quality-of-life perception that has been reported for VTE [18].

Percutaneous mechanical thrombectomy alone has also been reported in a small series for reduction of thrombus

burden and symptomatic improvement [19]. For patients who cannot receive thrombolytics and who have severe symptoms, thrombectomy strategies in addition to anticoagulation may be reasonable, although there is no relevant literature regarding the durability of these treatments and their long-term outcomes. Thus, optimal patient selection for more aggressive strategies versus anticoagulation alone may need further refinement to identify those who will benefit most. At present, the best available data suggest CDT in conjunction with anticoagulation should be reserved for select cases of proximal DVT in severely symptomatic patients with low bleeding risk [3,8,17].

Surgical Thrombectomy Techniques. Although the Society of Vascular Surgery guidelines recommend catheter-based therapies over open surgery for VTE [15], surgical thrombectomy with or without arteriovenous fistula creation and hybrid operative thrombectomy with iliac vein stenting has been explored as an alternative intervention for acute DVT. Hybrid techniques with thrombectomy and stenting have largely replaced adjunctive arteriovenous fistula creation. Available studies include case series, case control trials, and a few prospective trials showing improved patient outcomes with operative techniques but no large rigorous head-to-head controlled trials assessing the performance of operative strategy to catheter-based therapies or anticoagulation alone [20-23]. For patients who cannot receive thrombolytics and who have severe symptoms, thrombectomy strategies may be reasonable, although there is no relevant literature regarding the durability of these treatments and their long-term outcomes.

Variant 3: Acute femoropopliteal DVT with mild to moderate symptoms present for less than 14 days, otherwise healthy

Anticoagulation Alone. Femoropopliteal DVT carries a risk for proximal extension and PE and is therefore also treated with anticoagulation as a first-line therapy. Duration of anticoagulation is generally at least 3 months, with indications for indefinite anticoagulation remaining for those with unprovoked DVT and otherwise without contraindication to or significant bleeding risk with anticoagulation [5].

CDT/PMT. Despite the known risks of PTS in this cohort, the best prospective evidence to date with the ATTRACT trial has demonstrated no improvement in PTS at 2 years with more aggressive CDT over anticoagulation alone. There is no relevant literature regarding use of percutaneous mechanical thrombectomy or surgical

thrombectomy for those who cannot receive anticoagulation in this setting; however, extrapolation from the ATTRACT trial suggests this would not be of clinical benefit [8,15].

Graded Compression Stocking Therapy. Graded compression therapy with stockings has traditionally been recommended to address venous stasis changes and potentially prevent PTS; however, several recent randomized trials have found no specific benefit to compression therapy in preventing PTS [9-14]. Use of graded compression stockings in conjunction with additional measures, such as leg elevation, may be recommended in addition to anticoagulation on an individualized basis for patient comfort and symptom management.

Variant 4: Acute iliofemoral DVT and symptoms less than 14 days. Cross-sectional imaging consistent with May-Thurner syndrome

Anticoagulation Alone. Anticoagulation is generally a first-line therapy for acute iliofemoral DVT [5]. Presentation of acute left-sided DVT, particularly in otherwise young and healthy patients, should raise suspicion for a compression syndrome as there is a relatively higher incidence of iliac vein compression in this cohort (ie, May-Thurner Syndrome). As this finding may be underdiagnosed, many patients with iliofemoral DVT and an obstructive iliac vein lesion may be treated with anticoagulation alone. Recurrent VTE in the affected limb has been observed more frequently with anticoagulation alone compared with those who underwent additional treatment with thrombectomy and iliac vein stenting [24-26]. Despite a general consensus to treat iliac vein obstructive lesions with stents in addition to anticoagulation, there is no relevant literature rigorously testing this practice against anticoagulation alone in prospective randomized controlled trials.

CDT/PMT With or Without Stent Placement. Presentation of acute left-sided DVT, particularly in otherwise young and healthy patients, should raise suspicion for a compression syndrome as there is a relatively higher incidence of iliac vein compression in this cohort (ie, May-Thurner Syndrome). Because of the underlying anatomic compression, additional measures, including balloon angioplasty with stenting of the compressive lesion, have been described with reported benefit in a small retrospective series [27-29]. Although there is no relevant literature rigorously testing this practice against anticoagulation alone in prospective randomized controlled trials, the general consensus is to treat iliac vein obstructive lesions with stents in addition to anticoagulation as recurrent VTE in

the affected limb has been observed more frequently with anticoagulation alone [24-26].

Hybrid Surgical Thrombectomy With Stenting. Surgical thrombectomy/endovenectomy and iliac vein stenting have also been described in the setting of obstructive iliofemoral DVT with reported benefit in small retrospective series [23,30]; however, there is no relevant literature comparing this therapy against anticoagulation alone or anticoagulation with catheter-based therapy in prospective randomized controlled trials.

Variant 5: Acute iliofemoral DVT and limb-threatening ischemia (phlegmasia cerulea dolens)

Anticoagulation Alone. Rarely, acute iliofemoral DVT can present as a potentially life- and limb-threatening emergency known as phlegmasia cerulea dolens. Typically, a faster course of action is required above anticoagulation alone to prevent venous gangrene and potentially death.

CDT/PMT With or Without Stent Placement. Depending on the state of the threatened limb, techniques for rapid thrombus resolution have included surgical thrombectomy, percutaneous mechanical thrombectomy, and CDT [15,21,31,32]. Because of the rare nature of the condition, there is no relevant literature comparing outcomes between medical, catheter-based, or surgical therapies with prospective randomized controlled trials.

Surgical Thrombectomy With or Without Stent Placement. Depending on the state of the threatened limb, techniques for rapid thrombus resolution have included surgical thrombectomy, percutaneous mechanical thrombectomy, and CDT [15,21,31,32]. Because of the rare nature of the condition, there is no relevant literature comparing outcomes between medical, catheter-based, or surgical therapies with prospective randomized controlled trials.

Systemic Thrombolysis. Systemic intravenous delivery of thrombolytic medication has been performed in the past for severe symptoms of DVT [16]. Because of the risks of potential bleeding complications, systemic thrombolysis has largely been supplanted with catheter and surgical options that provide rapid treatment with lower risks of bleeding. However, because of the rare nature of the condition, there is no relevant literature directly comparing outcomes between medical, catheter-based, or

surgical therapies with prospective randomized controlled trials.

Variant 6: Iliofemoral DVT with persistent moderate symptoms at least 3 months after initial treatment with anticoagulation alone

Anticoagulation Alone. The best way to address chronic DVT to improve symptoms of PTS remains controversial. Anticoagulation is indicated if imaging demonstrates recurrent VTE or for patients with unprovoked DVT to prevent recurrent VTE [5]. In the absence of new DVT, symptoms may reflect chronic PTS. Interventional catheter-based techniques and surgery have been described to address chronic symptoms. There is no relevant literature assessing the performance of these different procedures in prospective randomized controlled trials.

CDT/PMT With or Without Stent Placement. Beneficial outcomes have been reported with chronic DVT symptoms in small retrospective uncontrolled series with venous recanalization and improvement of outflow with balloon angioplasty and stenting [33-36]. A post hoc subgroup analysis of patients randomized to CDT alone versus CDT with adjunctive balloon angioplasty showed beneficial outcomes with additional balloon angioplasty on symptomatic venous scales with patients presenting with subacute, rather than acute, DVT [37]. A trial examining the efficacy of endovascular intervention for chronic DVT with stenting of occluded segments with or without adjunctive endovenous ablation for saphenous vein reflux (Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy, NCT03250247: <https://clinicaltrials.gov/ct2/show/NCT03250247>) is currently underway.

Graded Compression Stocking Therapy. Graded compression therapy with stockings is commonly employed to manage venous stasis symptoms, although recent series have shown it has no proven benefit in preventing PTS [9-14]. Use of graded compression stockings in conjunction with additional measures, such as leg elevation, may be recommended on an individualized basis for patient comfort and symptom management.

Surgical Thrombectomy With or Without Stent Placement. There is no relevant literature examining the efficacy of surgical thrombectomy compared with control groups in prospective randomized trials. Observational case series demonstrating symptomatic improvement after surgical endovenectomy with iliac vein stenting [38,39], and with saphenofemoral venous bypass [40], have been described.

Variant 7: Acute iliofemoral DVT in a pregnant patient with moderate to severe symptoms

Anticoagulation Alone. VTE can complicate pregnancy, and first-line therapy is anticoagulation with low molecular weight heparin because of the lack of placental transgression [5]. There is no relevant literature providing guidance for duration of anticoagulation therapy, and individual patient management will factor risks of recurrent VTE and plans for future pregnancy. Although more aggressive thrombus removal strategies have been employed for pregnancy-related DVT, at present there is no relevant literature suggesting improvement in outcomes with use of these more aggressive therapies over anticoagulation alone in prospective randomized controlled trials. The available data suggest optimal management to be anticoagulation with low molecular weight heparin for iliofemoral DVT with mild to moderate symptoms and, potentially, catheter-based therapy in the second or third trimester for severe symptoms unrelenting after a trial of anticoagulation [41-43]. Surgical thrombectomy and arteriovenous fistula creation may be considered in the second or third trimester as well for severe refractory cases and to avoid radiation [21,44]. Depending on circumstances, optimal management could include anticoagulation until term, followed by CDT or thrombectomy if indicated for severe symptomatic DVT in the postpartum period [21,42,43].

CDT/PMT With or Without Stent Placement. There is no relevant literature defining the benefit of catheter-based therapies for pregnancy-related iliofemoral DVT compared with anticoagulation alone in prospective randomized controlled trials. Case series of patients presenting with severe symptoms treated with CDT including thrombolysis, percutaneous mechanical thrombectomy, angioplasty, and stenting have shown symptomatic efficacy and safety with respect to fetal and maternal health [42,44]. The issue of radiation exposure becomes critical, particularly in the first trimester, as reported radiation doses to the fetus have been estimated at 175 to 245 mGy, approximately 6- to 10-fold greater than environmental exposure [42]. Thus, local multidisciplinary ethics board discussion surrounding CDT in the first trimester is paramount. Second trimester CDT may be considered with severe symptoms refractory to anticoagulation, using shielding and principles of ALARA [42]. Depending on circumstances, optimal management could include anticoagulation until term, followed by CDT or thrombectomy if indicated for severe symptomatic DVT in the postpartum period [21,42,43].

Graded Compression Stocking Therapy. Graded compression therapy with stockings has traditionally been recommended to address venous stasis changes and potentially prevent PTS; however, several recent randomized trials have found no specific benefit to compression therapy in preventing PTS [9-14]. Use of graded compression stockings in conjunction with additional measures, such as leg elevation, may be recommended in addition to anticoagulation on an individualized basis for patient comfort and symptom management.

Surgical Thrombectomy With or Without Stent Placement. There is no relevant literature defining the benefit of surgical therapies for pregnancy-related iliofemoral DVT compared with anticoagulation or catheter-based therapies in prospective randomized controlled trials. Observational reports have described surgical thrombectomy with or without temporary arteriovenous fistula creation for management of DVT in pregnancy [21,44], with one study reporting 5 of 97 cases resulting in fetal demise, a 16.5% early thrombosis rate, and a secondary patency rate of 89.5% [45]. Surgical thrombectomy and arteriovenous fistula creation may be considered in the second or third trimester as well to avoid radiation [21,44]. Depending on circumstances, optimal management could include anticoagulation until term followed by thrombectomy if indicated for severe symptomatic DVT in the postpartum period [21,43].

SUMMARY OF RECOMMENDATIONS

- **Variant 1:** Anticoagulation alone is usually appropriate for a patient with acute iliofemoral DVT with mild symptoms <14 days, otherwise healthy.
- **Variant 2:** Anticoagulation alone or in conjunction with CDT/PMT with or without stent placement is usually appropriate for a patient with acute iliofemoral DVT with moderate to severe symptoms present for <14 days, otherwise healthy. These procedures may be complementary (ie, both may be performed to effectively manage the patient's care), particularly in patients <65 years of age.
- **Variant 3:** Anticoagulation alone is usually appropriate for a patient with acute femoropopliteal DVT with mild to moderate symptoms present for <14 days, otherwise healthy.
- **Variant 4:** Additional CDT/PMT with or without stent placement in conjunction with anticoagulation is usually appropriate for a patient with acute iliofemoral DVT and symptoms <14

days when cross-sectional imaging of the patient is consistent with May-Thurner syndrome.

- **Variant 5:** CDT/PMT with or without stent placement or surgical thrombectomy with or without stent placement is usually appropriate for a patient with acute iliofemoral DVT and limb-threatening ischemia (phlegmasia cerulea dolens). These interventions are equivalent alternatives (ie, only one procedure will be ordered to provide the clinical information to effectively manage the patient's care).
- **Variant 6:** Anticoagulation alone, CDT/PMT with or without stent placement, or graded compression stocking therapy may be appropriate for a patient with iliofemoral DVT with persistent moderate symptoms at least 3 months after initial treatment with anticoagulation alone. The panel did not agree on recommending surgical thrombectomy with or without stent placement for this particular clinical scenario. There is insufficient medical literature to conclude whether or not these patients would benefit from this intervention. Intervention in this patient population is controversial but may be appropriate.
- **Variant 7:** Anticoagulation alone is usually appropriate for a patient with acute iliofemoral DVT in a pregnant patient with moderate to severe symptoms.

SUPPORTING DOCUMENTS

The evidence table, literature search, and appendix for this topic are available at <https://acsearch.acr.org/list>. The appendix includes the strength of evidence assessment and rating round tabulations for each recommendation.

For additional information on the Appropriateness Criteria methodology and other supporting documents go to www.acr.org/ac.

SAFETY CONSIDERATIONS IN PREGNANT PATIENTS

Imaging of the pregnant patient can be challenging, particularly with respect to minimizing radiation exposure and risk. For further information and guidance, see the following ACR documents:

- ACR-SPR Practice Parameter for the Safe and Optimal Performance of Fetal Magnetic Resonance Imaging (MRI) [46]
- ACR-SPR Practice Parameter for Imaging Pregnant or Potentially Pregnant Adolescents and Women With Ionizing Radiation [47]

- ACR-ACOG-AIUM-SMFM-SRU Practice Parameter for the Performance of Standard Diagnostic Obstetrical Ultrasound [48]
- ACR Manual on Contrast Media [49]
- ACR Guidance Document on MR Safe Practices: 2013 [50]

REFERENCES

1. Grosse SD, Nelson RE, Nyarko KA, Richardson LC, Raskob GE. The economic burden of incident venous thromboembolism in the United States: a review of estimated attributable healthcare costs. *Thromb Res* 2016;137:3-10.
2. Sudheendra D, Vedantham S. Catheter-directed therapy options for iliofemoral venous thrombosis. *Surg Clin North Am* 2018;98:255-65.
3. Haig Y, Enden T, Grotta O, et al. Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial. *Lancet Haematol* 2016;3:e64-71.
4. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012;141:e419S-96S.
5. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report. *Chest* 2016;149: 315-52.
6. Minocha J, Smith AM, Kapoor BS, et al. ACR Appropriateness Criteria® Radiologic Management of Venous Thromboembolism-Inferior Vena Cava Filters. *J Am Coll Radiol* 2019;16:S214-26.
7. Muriel A, Jimenez D, Aujesky D, et al. Survival effects of inferior vena cava filter in patients with acute symptomatic venous thromboembolism and a significant bleeding risk. *J Am Coll Cardiol* 2014;63:1675-83.
8. Vedantham S, Goldhaber SZ, Julian JA, et al. Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. *N Engl J Med* 2017;377:2240-52.
9. Burgstaller JM, Steurer J, Held U, Amann-Vesti B. Efficacy of compression stockings in preventing post-thrombotic syndrome in patients with deep venous thrombosis: a systematic review and meta-analysis. *Vasa* 2016;45:141-7.
10. Jayaraj A, Meissner M. Impact of graduated compression stockings on the prevention of post-thrombotic syndrome—results of a randomized controlled trial. *Phlebology* 2015;30:541-8.
11. Kahn SR, Shapiro S, Wells PS, et al. Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. *Lancet* 2014;383:880-8.
12. Mol GC, van de Ree MA, Klok FA, et al. One versus two years of elastic compression stockings for prevention of post-thrombotic syndrome (OCTAVIA study): randomised controlled trial. *BMJ* 2016;353:i2691.
13. Skervin AL, Thapar A, Franchini AJ, Prandoni P, Shalhoub J, Davies AH. Systematic review and meta-analysis of utility of graduated compression stockings in prevention of post-thrombotic syndrome. *Eur J Vasc Endovasc Surg* 2016;51:838-45.
14. Subbiah R, Aggarwal V, Zhao H, Kolluri R, Chatterjee S, Bashir R. Effect of compression stockings on post thrombotic syndrome in patients with deep vein thrombosis: a meta-analysis of randomised controlled trials. *Lancet Haematol* 2016;3:e293-300.
15. Meissner MH. Rationale and indications for aggressive early thrombus removal. *Phlebology* 2012;27(Suppl 1):78-84.
16. Watson L, Broderick C, Armon MP. Thrombolysis for acute deep vein thrombosis. *Cochrane Database Syst Rev* 2016;11:CD002783.
17. Comerota AJ, Kearon C, Gu CS, et al. Endovascular thrombus removal for acute iliofemoral deep vein thrombosis. *Circulation* 2019;139:1162-73.
18. Hogg K, Kimpton M, Carrier M, Coyle D, Forgie M, Wells P. Estimating quality of life in acute venous thrombosis. *JAMA Intern Med* 2013;173:1067-72.
19. Cakir V, Gulcu A, Akay E, et al. Use of percutaneous aspiration thrombectomy vs. anticoagulation therapy to treat acute iliofemoral venous thrombosis: 1-year follow-up results of a randomised, clinical trial. *Cardiovasc Interv Radiol* 2014;37:969-76.
20. Holper P, Kotelis D, Attigah N, Hyhlik-Durr A, Bockler D. Longterm results after surgical thrombectomy and simultaneous stenting for symptomatic iliofemoral venous thrombosis. *Eur J Vasc Endovasc Surg* 2010;39:349-55.
21. Koopmann MC, McLafferty RB. Advances in operative thrombectomy for lower extremity venous thrombosis. *Surg Clin North Am* 2018;98: 267-77.
22. Plate G, Eklof B, Norgren L, Ohlin P, Dahlstrom JA. Venous thrombectomy for iliofemoral vein thrombosis—10-year results of a prospective randomised study. *Eur J Vasc Endovasc Surg* 1997;14: 367-74.
23. Rodriguez LE, Aboukheir-Aboukheir A, Figueira-Vicente R, et al. Hybrid operative thrombectomy is noninferior to percutaneous techniques for the treatment of acute iliofemoral deep venous thrombosis. *J Vasc Surg Venous Lymphat Disord* 2017;5:177-84.
24. Birn J, Vedantham S. May-Thurner syndrome and other obstructive iliac vein lesions: meaning, myth, and mystery. *Vasc Med* 2015;20:74-83.
25. Hartung O, Benmiloud F, Barthelemy P, Dubuc M, Boufi M, Alimi YS. Late results of surgical venous thrombectomy with iliocaval stenting. *J Vasc Surg* 2008;47:381-7.
26. Mickley V, Schwagierek R, Rilinger N, Gorich J, Sunder-Plassmann L. Left iliac venous thrombosis caused by venous spur: treatment with thrombectomy and stent implantation. *J Vasc Surg* 1998;28:492-7.
27. Ming ZB, Li WD, Yuan RF, Li XQ, Ding WB. Effectiveness of catheter directed thrombolysis and stent implantation on iliofemoral vein thrombosis caused by iliac vein compression. *J Thromb Thrombolysis* 2017;44:254-60.
28. Park JY, Ahn JH, Jeon YS, Cho SG, Kim JY, Hong KC. Iliac vein stenting as a durable option for residual stenosis after catheter-directed thrombolysis and angioplasty of iliofemoral deep vein thrombosis secondary to May-Thurner syndrome. *Phlebology* 2014;29:461-70.
29. Zhu QH, Zhou CY, Chen Y, et al. Percutaneous manual aspiration thrombectomy followed by stenting for iliac vein compression syndrome with secondary acute isolated iliofemoral deep vein thrombosis: a prospective study of single-session endovascular protocol. *Eur J Vasc Endovasc Surg* 2014;47:68-74.
30. Igari K, Kudo T, Toyofuku T, Jibiki M, Inoue Y. Surgical thrombectomy and simultaneous stenting for deep venous thrombosis caused by iliac vein compression syndrome (May-Thurner syndrome). *Ann Thorac Cardiovasc Surg* 2014;20:995-1000.
31. Laohapensang K, Hanpipat S, Aworn S, Orrapin S. Surgical venous thrombectomy for phlegmasia cerulea dolens and venous gangrene of the lower extremities. *J Med Assoc Thai* 2013;96:1463-9.
32. Avgerinos ED, Hager ES, Naddaf A, Dillavou E, Singh M, Chaer RA. Outcomes and predictors of failure of thrombolysis for iliofemoral deep venous thrombosis. *J Vasc Surg Venous Lymphat Disord* 2015;3: 35-41.
33. Ruihua W, Xin W, Guang L, et al. Technique and clinical outcomes of combined stent placement for postthrombotic chronic total occlusions of the iliofemoral veins. *J Vasc Interv Radiol* 2017;28:373-9.
34. Sarici IS, Yanar F, Agcaoglu O, et al. Our early experience with iliofemoral vein stenting in patients with post-thrombotic syndrome. *Phlebology* 2014;29:298-303.
35. Ye K, Lu X, Jiang M, et al. Technical details and clinical outcomes of transpopliteal venous stent placement for postthrombotic chronic total occlusion of the iliofemoral vein. *J Vasc Interv Radiol* 2014;25: 925-32.
36. Yin M, Shi H, Ye K, et al. Clinical assessment of endovascular stenting compared with compression therapy alone in post-

- thrombotic patients with iliofemoral obstruction. *Eur J Vasc Endovasc Surg* 2015;50:101-7.
37. Zhang X, Ren Q, Jiang X, et al. A prospective randomized trial of catheter-directed thrombolysis with additional balloon dilatation for iliofemoral deep venous thrombosis: a single-center experience. *Cardiovasc Intervent Radiol* 2014;37:958-68.
38. Vogel D, Comerota AJ, Al-Jabouri M, Assi ZI. Common femoral endovenectomy with ilio caval endoluminal recanalization improves symptoms and quality of life in patients with postthrombotic iliofemoral obstruction. *J Vasc Surg* 2012;55:129-35.
39. Pokrovsky A, Ignatyev I, Gradusov E. First experience of performing hybrid operations in chronic venous obstructions of iliofemoral segments in patients with postthrombotic syndrome. *Vasc Endovascular Surg* 2017;51:447-52.
40. Shaydakov E, Poremskaya O, Geroulakos G. The May-Husni procedure: a reappraisal. *Eur J Vasc Endovasc Surg* 2015;50:513-7.
41. Bates SM, Middeldorp S, Rodger M, James AH, Greer I. Guidance for the treatment and prevention of obstetric-associated venous thromboembolism. *J Thromb Thrombolysis* 2016;41:92-128.
42. Bloom AI, Farkas A, Kalish Y, Elchalal U, Spectre G. Pharmacomechanical catheter-directed thrombolysis for pregnancy-related iliofemoral deep vein thrombosis. *J Vasc Interv Radiol* 2015;26:992-1000.
43. Devis P, Knutinen MG. Deep venous thrombosis in pregnancy: incidence, pathogenesis and endovascular management. *Cardiovasc Diagn Ther* 2017;7:S309-19.
44. Herrera S, Comerota AJ, Thakur S, et al. Managing iliofemoral deep venous thrombosis of pregnancy with a strategy of thrombus removal is safe and avoids post-thrombotic morbidity. *J Vasc Surg* 2014;59:456-64.
45. Pillny M, Sandmann W, Luther B, et al. Deep venous thrombosis during pregnancy and after delivery: indications for and results of thrombectomy. *J Vasc Surg* 2003;37:528-32.
46. American College of Radiology. ACR-SPR practice parameter for the safe and optimal performance of fetal magnetic resonance imaging (MRI). Available at: <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/mr-fetal.pdf>. Accessed November 29, 2019.
47. American College of Radiology. ACR-SPR practice parameter for imaging pregnant or potentially pregnant adolescents and women with ionizing radiation. Available at: <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/pregnant-pts.pdf>. Accessed November 29, 2019.
48. American College of Radiology. ACR-ACOG-AIUM-SMFM-SRU practice parameter for the performance of standard diagnostic obstetrical ultrasound. Available at: <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/us-ob.pdf>. Accessed November 29, 2019.
49. American College of Radiology. Manual on contrast media. Available at: <https://www.acr.org/Clinical-Resources/Contrast-Manual>. Accessed November 29, 2019.
50. Kanal E, Barkovich AJ, Bell C, et al. ACR guidance document on MR safe practices: 2013. *J Magn Reson Imaging* 2013;37:501-30.